Actionable news
All posts from Actionable news
Actionable news in AMGN: Amgen Inc.,

Amgen, Cytokinetics heart failure drug succeeds in mid-stage study

Oct 27 (Reuters) - Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study.

The 448 patients in the trial were given an oral formulation of the drug omecamtiv mecarbil for 20 weeks and observed for 24 weeks, the companies said in a joint statement.

An intravenous formulation of the drug failed in 2013, leaving its future uncertain. The tests on the oral formulation ran longer than the...